ADR Biomedical HoldingsTSE:3750 +0.37%30 Shareholder Yield % is 33.83% as of Mar. 2026, which is 1333% above its 10-year median of 2.36. GuruFocus rates TSE:3750 with a GF Score™ of 30/100 and a GF Value™ of 円40.38 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,296 Biotechnology companies, ADR Biomedical Holdings ranks better than 97.53% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, ADR Biomedical Holdings's Shareholder Yield % was 33.83%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
ADR Biomedical Holdings Shareholder Yield % Related Terms
ADR Biomedical Holdings Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for ADR Biomedical Holdings's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3750 vs VRTX, REGN, ALNY: Shareholder Yield % Comparison
For the Biotechnology subindustry, ADR Biomedical Holdings's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
ADR Biomedical Holdings (TSE:3750) has a Shareholder Yield % of 33.83% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on ADR Biomedical Holdings and its competitors. This is 1333% above median its historical median of 2.36. According to the industry distribution chart, ADR Biomedical Holdings ranks #32 out of 1296 companies in the Biotechnology industry, placing it in the top 2.5%.
Is ADR Biomedical Holdings' Shareholder Yield % too high?
ADR Biomedical Holdings' current Shareholder Yield % of 33.83% is 1333% above median its 10-year median of 2.36. Based on the distribution chart, ADR Biomedical Holdings ranks #32 out of 1296 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #32 out of 1296 companies for Shareholder Yield %. This places ADR Biomedical Holdings in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Shareholder Yield % is 33.83%, which is 1333% above median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.38, compared to a current price of 円808.00 — trading 1901% above its estimated fair value. The current Shareholder Yield % is 33.83%, which is 1333% above median its 10-year median of 2.36. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Shareholder Yield % is 33.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円808.00 is trading 1901% above its estimated GF Value™ of 円40.38.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
Shareholder Yield %: 33.83% (1333% above median its 10-year median of 2.36)
GF Value™: 円40.38 vs. price of 円808.00 (1901% above fair value)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score
Get the complete analysis for TSE:3750
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
